Tucatinib
- TRADE NAME: Tukysa (Seattle Genetics)
- INDICATIONS: In combination with trastuzumab and capecitabine, for the treatment of unresectable or metastatic HER2-positive breast cancer.
- CLASS: Kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: approx. 8.5 hours
FDA APPROVAL DATE: 04/17/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:CYP2C8 Inducers, CYP2C8 Inhibitors, CYP3A Inducers, CYP3A Substrates, CYP3A Substrates, Digoxin, Gemfibrozil, Itraconazole, Metformin, Midazolam, P-gp Substrates, Repaglinide, Rifampin
Tucatinib can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to the fetus.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric